Target and disease logic
Prioritize diseases, targets, and mechanisms where Bangladesh can build a meaningful research foothold.
Bangladesh has strong pharma manufacturing capacity, but original small-molecule discovery remains largely absent. Chem2Cure aims to build the scientific habits, teams, and workflows needed to change that trajectory.
Press play, or tap any stage. One molecule travels down through eight gates, from the first idea to a patient, and a few of its companions drop out at every one. Watch how few make it. The figures are typical industry averages: they change from one disease and one company to the next, and they are here to show the shape of the journey, not to describe any single project.
This is the part Chem2Cure trains people for.
A new medicine passes through nine stages before a patient can take it, and more than a decade usually passes along the way. Most candidates fail, and each stage needs different people, instruments, and judgement. The point of showing it is not to discourage anyone: it is to be clear about which part of this chain Bangladesh is currently equipped for, and which part we are trying to build.
Scroll sideways to see all nine stages
The country's pharmaceutical industry is genuinely strong, and supplies most of the domestic market. But that strength lies downstream of everything above: it begins once a molecule already exists, has already been proven, and its patent has expired. None of the nine stages above happens here at any scale.
Making and formulating a known molecule is manufacturing. Deciding which molecule to make in the first place is discovery, and it needs chemists trained to read a target, design a series, and judge the data. That training is what Chem2Cure exists to provide.
Timelines are typical industry figures and vary widely by therapeutic area. Most programmes never reach the next stage at all.
Discovery is not one tool or one assay. It is a disciplined loop between chemistry, biology, computation, pharmacology, safety, and decision making.
Look again at the first two stages above. Target work and hit finding are where programmes lose years, because the only way to know whether a molecule works has traditionally been to make it and test it. That is the part computation changes. Phase I to III still take their years, whatever anyone claims.
Screening and generative design narrow the field computationally before anything is weighed out, and retrosynthesis checks that what survives can actually be built from material you can buy. The compounds that reach the bench are then the ones most likely to matter, which is how months of synthesis get saved.
Nothing here removes the experiment. A predicted score is a hypothesis, and the assay is still what decides. What changes is how many hypotheses you have to pay for before one works.
Prioritize diseases, targets, and mechanisms where Bangladesh can build a meaningful research foothold.
Use literature, patents, virtual screening, fragment thinking, and existing chemical matter to identify starting points.
Design analogs, build focused libraries, interpret activity, and connect molecular changes to biological response.
Introduce solubility, permeability, stability, selectivity, and early safety thinking before expensive failure.
Prepare the evidence package needed for partnerships, grants, and translational next steps.
Input: target structure, known ligands, disease context
Model: structure prediction, docking, affinity ranking, property filters
Chemist review: synthetic feasibility, novelty, SAR hypothesis
Output: prioritized molecules for purchase, synthesis, or collaboration
Chem2Cure introduces AI as an integrated research workflow: structure prediction, docking, library triage, property prediction, and literature intelligence. Every output still needs human medicinal chemistry judgment.
Dengue, emerging viral threats, and regionally relevant diseases where local need is high.
Capacity building around diagnosis, therapy discovery, and patient-centered translational research.
Skill transfer toward fragrances, food chemicals, agrochemicals, and higher-value chemical industries.
Training chemists for contract research, analytical documentation, and global partnership standards.